Cargando…

Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs

BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cru...

Descripción completa

Detalles Bibliográficos
Autores principales: Aparicio-Burgos, José E., Ochoa-García, Laucel, Zepeda-Escobar, José Antonio, Gupta, Shivali, Dhiman, Monisha, Martínez, José Simón, de Oca-Jiménez, Roberto Montes, Arreola, Margarita Val, Barbabosa-Pliego, Alberto, Vázquez-Chagoyán, Juan C., Garg, Nisha Jain
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098890/
https://www.ncbi.nlm.nih.gov/pubmed/21625470
http://dx.doi.org/10.1371/journal.pntd.0001050
_version_ 1782204014719401984
author Aparicio-Burgos, José E.
Ochoa-García, Laucel
Zepeda-Escobar, José Antonio
Gupta, Shivali
Dhiman, Monisha
Martínez, José Simón
de Oca-Jiménez, Roberto Montes
Arreola, Margarita Val
Barbabosa-Pliego, Alberto
Vázquez-Chagoyán, Juan C.
Garg, Nisha Jain
author_facet Aparicio-Burgos, José E.
Ochoa-García, Laucel
Zepeda-Escobar, José Antonio
Gupta, Shivali
Dhiman, Monisha
Martínez, José Simón
de Oca-Jiménez, Roberto Montes
Arreola, Margarita Val
Barbabosa-Pliego, Alberto
Vázquez-Chagoyán, Juan C.
Garg, Nisha Jain
author_sort Aparicio-Burgos, José E.
collection PubMed
description BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cruzi infection in a canine model. Dogs were immunized with antigen-encoding plasmids and cytokine adjuvants, and two weeks after the last immunization, challenged with T. cruzi trypomastigotes. We measured antibody responses by ELISA and haemagglutination assay, parasitemia and infectivity to triatomines by xenodiagnosis, and performed electrocardiography and histology to assess myocardial damage and tissue pathology. RESULTS: Vaccination with TcVac1 elicited parasite-and antigen-specific IgM and IgG (IgG2>IgG1) responses. Upon challenge infection, TcVac1-vaccinated dogs, as compared to non-vaccinated controls dogs, responded to T. cruzi with a rapid expansion of antibody response, moderately enhanced CD8(+) T cell proliferation and IFN-γ production, and suppression of phagocytes’ activity evidenced by decreased myeloperoxidase and nitrite levels. Subsequently, vaccinated dogs controlled the acute parasitemia by day 37 pi (44 dpi in non-vaccinated dogs), and exhibited a moderate decline in infectivity to triatomines. TcVac1-immunized dogs did not control the myocardial parasite burden and electrocardiographic and histopatholgic cardiac alterations that are the hallmarks of acute Chagas disease. During the chronic stage, TcVac1-vaccinated dogs exhibited a moderate decline in cardiac alterations determined by EKG and anatomo-/histo-pathological analysis while chronically-infected/non-vaccinated dogs continued to exhibit severe EKG alterations. CONCLUSIONS: Overall, these results demonstrated that TcVac1 provided a partial resistance to T. cruzi infection and Chagas disease, and provide an impetus to improve the vaccination strategy against Chagas disease.
format Text
id pubmed-3098890
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30988902011-05-27 Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs Aparicio-Burgos, José E. Ochoa-García, Laucel Zepeda-Escobar, José Antonio Gupta, Shivali Dhiman, Monisha Martínez, José Simón de Oca-Jiménez, Roberto Montes Arreola, Margarita Val Barbabosa-Pliego, Alberto Vázquez-Chagoyán, Juan C. Garg, Nisha Jain PLoS Negl Trop Dis Research Article BACKGROUND: Trypanosoma cruzi, the etiologic agent of Chagas Disease, is a major vector borne health problem in Latin America and an emerging infectious disease in the United States. METHODS: We tested the efficacy of a multi-component DNA-prime/DNA-boost vaccine (TcVac1) against experimental T. cruzi infection in a canine model. Dogs were immunized with antigen-encoding plasmids and cytokine adjuvants, and two weeks after the last immunization, challenged with T. cruzi trypomastigotes. We measured antibody responses by ELISA and haemagglutination assay, parasitemia and infectivity to triatomines by xenodiagnosis, and performed electrocardiography and histology to assess myocardial damage and tissue pathology. RESULTS: Vaccination with TcVac1 elicited parasite-and antigen-specific IgM and IgG (IgG2>IgG1) responses. Upon challenge infection, TcVac1-vaccinated dogs, as compared to non-vaccinated controls dogs, responded to T. cruzi with a rapid expansion of antibody response, moderately enhanced CD8(+) T cell proliferation and IFN-γ production, and suppression of phagocytes’ activity evidenced by decreased myeloperoxidase and nitrite levels. Subsequently, vaccinated dogs controlled the acute parasitemia by day 37 pi (44 dpi in non-vaccinated dogs), and exhibited a moderate decline in infectivity to triatomines. TcVac1-immunized dogs did not control the myocardial parasite burden and electrocardiographic and histopatholgic cardiac alterations that are the hallmarks of acute Chagas disease. During the chronic stage, TcVac1-vaccinated dogs exhibited a moderate decline in cardiac alterations determined by EKG and anatomo-/histo-pathological analysis while chronically-infected/non-vaccinated dogs continued to exhibit severe EKG alterations. CONCLUSIONS: Overall, these results demonstrated that TcVac1 provided a partial resistance to T. cruzi infection and Chagas disease, and provide an impetus to improve the vaccination strategy against Chagas disease. Public Library of Science 2011-05-17 /pmc/articles/PMC3098890/ /pubmed/21625470 http://dx.doi.org/10.1371/journal.pntd.0001050 Text en Aparicio-Burgos et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Aparicio-Burgos, José E.
Ochoa-García, Laucel
Zepeda-Escobar, José Antonio
Gupta, Shivali
Dhiman, Monisha
Martínez, José Simón
de Oca-Jiménez, Roberto Montes
Arreola, Margarita Val
Barbabosa-Pliego, Alberto
Vázquez-Chagoyán, Juan C.
Garg, Nisha Jain
Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title_full Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title_fullStr Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title_full_unstemmed Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title_short Testing the Efficacy of a Multi-Component DNA-Prime/DNA-Boost Vaccine against Trypanosoma cruzi Infection in Dogs
title_sort testing the efficacy of a multi-component dna-prime/dna-boost vaccine against trypanosoma cruzi infection in dogs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098890/
https://www.ncbi.nlm.nih.gov/pubmed/21625470
http://dx.doi.org/10.1371/journal.pntd.0001050
work_keys_str_mv AT aparicioburgosjosee testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT ochoagarcialaucel testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT zepedaescobarjoseantonio testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT guptashivali testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT dhimanmonisha testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT martinezjosesimon testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT deocajimenezrobertomontes testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT arreolamargaritaval testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT barbabosapliegoalberto testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT vazquezchagoyanjuanc testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs
AT gargnishajain testingtheefficacyofamulticomponentdnaprimednaboostvaccineagainsttrypanosomacruziinfectionindogs